A remedy for hyperuricemia which comprises a hydantoin derivative represented by general formula (I) or a salt thereof as the active ingredient, wherein Q represents cyclohexyl, cycloheptyl, cyclooctyl, 2,5-dimethylthien-3-yl, indan-2-yl or 2,5-dichlorophenyl. The uricosuric agent exerts a potent uricosuric effect on an animal experiment model while sustaining or gradually increasing the urine volume. Further, it has a low toxicity. Thus it is useful in the treatment of hyperuricemia or in the treatment and prevention of gout. It is expected that the effect of the uricosuric agent of sustaining or gradually increasing the urine volume would relieve the load on a patient of taking a large amount of water.
[EN] GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DES KINASES GCN2 ET PERK ET LEURS MÉTHODES D'UTILISATION
申请人:DECIPHERA PHARMACEUTICALS LLC
公开号:WO2022109001A1
公开(公告)日:2022-05-27
Described herein are compounds that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
Process for the preparation of sulfonylamino benzophenones
申请人:ELI LILLY AND COMPANY
公开号:EP0093590A1
公开(公告)日:1983-11-09
A novel process is provided which roduces intermediates useful in the regiospecific synthes s of benzimidazole antiviral agents. The process comprises reacting a 3-fluoro-4-nitrobenzophenone with an anion of a sL fonamide to yield a 3-substitutedsulfonylamino-4-nitrobenzohenone. Novel intermediates are also disclosed.
According to the present invention there is provided a process for producing an acid anhydride by reacting a carboxylic acid, preferably a carboxylic acid having a polymerizable group, with a sulfonyl halide compound in the presence of a tertiary amine or in the presence of a tertiary amine and an inorganic base, wherein the tertiary amine or the tertiary amine and the inorganic base are used in an amount of 0.9 to 1.2 equivalents relative to the acid generated from the sulfonyl halide compound.
NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR
申请人:Public University Corporation Yokohama City
University
公开号:EP3321252A1
公开(公告)日:2018-05-16
The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof.
(In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents hydrogen, alkyl, alkenyl, alkynyl or halo; each R5 independently represents alkyl, alkenyl, alkynyl or halo; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.